Christopher Kiritsy's most recent trade in Palvella Therapeutics Inc. was a trade of 12,350 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Palvella Therapeutics Inc | Christopher Kiritsy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 12,350 | 12,350 | - | - | Non-Qualified Stock Option (right to buy) | |
| Palvella Therapeutics Inc | Christopher Kiritsy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 24,700 | 24,700 | - | - | Stock Option (right to buy) | |
| Pieris Pharmaceuticals Inc | Christopher Kiritsy | Director | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 25 May 2023 | 10,000 | 20,000 (0%) | 0% | 0.9 | 8,500 | Common Stock |
| Pieris Pharmaceuticals Inc | Christopher Kiritsy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) |